The ADAPT-PD trial validated aDBS's safety and efficacy, showing advantages over traditional continuous DBS methods. The ...
For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results